In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biotech Pipelines: Prices Never Lower

Executive Summary

Pharmaceutical companies love to deals early, at R&D stage, or late, when products are ready to be marketed. But they hate doing deals in the middle. Why? The risk to too high. Everyone knows what to expect from late stage deals; and no one's going to get killed for an early-stage deal that goes wrong. But Phase I and II deals often carry high price tags and chancy pay-offs.

You may also be interested in...



Managed Care Tackles Biotech Blockbusters

Manufacturers in the past haven't paid much heed to health plans' half-hearted efforts to reign in biotech drug spending. They figure if the drug is good enough, payers have to cover it. But health plans are for the first time serious about managing specialty pharma spending. Manufacturers should take heed because the impact on their revenues and marketing strategies could be significant.

COVID-19 Vaccine Strain Updates Don’t Exactly Fit Flu Model

Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.

Lundbeck Ready To Funnel 2022 Growth Into Expected Alzheimer’s Agitation Launch

The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel